INV 300
Alternative Names: INV-300Latest Information Update: 30 Nov 2022
At a glance
- Originator INVENT Pharmaceuticals
- Class Antidementias; Nootropics; Small molecules
- Mechanism of Action Serotonin 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Cognition disorders
Most Recent Events
- 30 Nov 2022 Preclinical trials in Alzheimer's disease in USA prior to 30 November 2022 (PO) (Invent Pharmaceuticals pipeline, November 2022)
- 30 Nov 2022 Preclinical trials in Cognition disorders in USA prior to 30 November 2022 (PO) (Invent Pharmaceuticals pipeline, November 2022)
- 30 Nov 2022 Invent Pharmaceuticals plans a phase II trial for Alzheimer's disease and cognitive impairment associated with schizophrenia (Invent Pharmaceuticals pipeline, November 2022)